Evaluation of absorbed dose in Gadolinium neutron capture therapy

• Autorzy: Gayane Abdullaeva , Gulnara Djuraeva , Andrey Kim , Yuriy Koblik , Gairatulla Kulabdullaev , Turdimukhammad Rakhmonov , Shavkat Saytjanov
• Języki publikacji: EN

Abstrakty

EN

Gadolinium neutron capture therapy (GdNCT) is used for treatment of radioresistant malignant tumors. The absorbed dose in GdNCT can be divided into four primary dose components: thermal neutron, fast neutron, photon and natural gadolinium doses. The most significant is the dose created by natural gadolinium. The amount of gadolinium at the irradiated region is changeable and depends on the gadolinium delivery agent and on the structure of the location where the agent is injected. To de- fine the time dependence of the gadolinium concentration ρ(t) in the irradiated region the pharmacokinetics of gadolinium delivery agent (Magnevist) was studied at intratumoral injection in mice and intramuscular injection in rats. A polynomial approximation was applied to the experimental data and the influence of ρ(t) on the relative change of the absorbed dose of gadolinium was studied.

Słowa kluczowe

EN

GdNCT; Magnevist; absorbed dose; kerma; amount of gadolinium

• Czasopismo: Open Physics
• Rocznik: 2015
• Tom: 13
• Numer: 1

Daty

otrzymano

2014-06-20

zaakceptowano

2015-01-01

online

2015-02-27

Twórcy

autor

Gayane Abdullaeva

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

autor

Gulnara Djuraeva

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

autor

Andrey Kim

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

autor

Yuriy Koblik

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

autor

Gairatulla Kulabdullaev

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

autor

Turdimukhammad Rakhmonov

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

autor

Shavkat Saytjanov

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

Bibliografia

• [1] H.J. Weinmann, R.C. Brasch, W.R. Press, G.S. Wesbey, Am. J.Roentgenol. 142, 619 (1984)[Crossref]
• [2] M. Magerstadt et al., Magn. Reson. Med. 3, 808 (1986)[Crossref]
• [3] G.De Stasio et al., Cancer Res. 61, 4272 (2001)
• [4] Yu.N. Koblik et al., Med. Phys. (Russia) 51, 31 (2011)
• [5] A.A. Kim et al., IJNESE. 4, 43 (2014)
• [6] G.A. Kulabdullaev et al., Uzb. Phys. J. 15, 127 (2013)
• [7] A-F. Miller, Ch.J. Halkides, A.G. Redfield, Biochemistry 32, 7367(1993)[Crossref]
• [8] J. Stepanek, Excerpta Med. Int. Cong. Series 1132, 425 (1997)
• [9] C.K.C. Wang, M. Sutton, T.M. Evans, B.H. Laster, A microdosimetricstudy of 10B(n,γ)7Li and 157Gd(n,) reactions for neutroncapture therapy, In Proceedings of the Sixth InternationalRadiopharmaceutical Dosimetry Symposium, (Institute for Scienceand Education, Oak Ridge, TN 1999), 336
• [10] T. Goorley, H. Nikjoo, Radiat. Res. 54, 556 (2000)
• [11] M. Rivard, J. Stepanek, Med. Phys. 27, 1544 (2000)
• [12] S.A. Klykov et al., At. Energ. 91, 6 ( 2001)
• [13] Y. Sakurai, T. Kobayashi, J. Nucl. Sci. Technol. S2, 1294 ( 2002)[Crossref]
• [14] I. Sheino, V. Khokhlov, V. Kulakov, K. Zaitsev, In: S. Taskaev(Ed.), Estimation of neutron kerma in biological tissue containingboron and gadolinium compounds for neutron capture therapy,Proceedings Intern. Symposium on Boron Neutron CaptureTherapy, July 7-9, 2004, Novosibirsk, Russia (2004)
• [15] K. Zaitsev et al., In: S. Taskaev (Ed.), NCT at the MEPhI reactor,Proceedings Intern. Symposium on Boron Neutron CaptureTherapy, July 7-9, 2004, Novosibirsk, Russia (2004)
• [16] G.A. Abdullaeva et al., Bull. Rus. Acad. 73, 512 (2009)
• [17] G.A. Abdullaeva et al., Atom. Energy 115, 166 (2013)
• [18] H. Tokumitsu, H. Ichikawa, Y. Fukumori, J. Pharm. Res. 16, 1830(1999)[Crossref]
• [19] B. Hofmann et al., Invest. Radiol. 34, 126 (1999)[Crossref]

Identyfikatory

DOI

10.1515/phys-2015-0022